nodes	percent_of_prediction	percent_of_DWPC	metapath
Paroxetine—SLC6A4—conduct disorder	0.514	0.566	CbGaD
Paroxetine—HTR2A—conduct disorder	0.395	0.435	CbGaD
Paroxetine—SLC6A3—Clearance of dopamine—MAOA—conduct disorder	0.00627	0.0809	CbGpPWpGaD
Paroxetine—SLC6A2—autonomic nervous system—conduct disorder	0.00433	0.313	CbGeAlD
Paroxetine—SLC6A4—Serotonin Transporter Activity—MAOA—conduct disorder	0.00291	0.0376	CbGpPWpGaD
Paroxetine—SLC6A3—Neurotransmitter Clearance In The Synaptic Cleft—COMT—conduct disorder	0.00288	0.0372	CbGpPWpGaD
Paroxetine—SLC6A3—Neurotransmitter Clearance In The Synaptic Cleft—MAOA—conduct disorder	0.00286	0.0369	CbGpPWpGaD
Paroxetine—HTR2A—autonomic nervous system—conduct disorder	0.0026	0.188	CbGeAlD
Paroxetine—SLC6A2—Monoamine Transport—SLC6A4—conduct disorder	0.00142	0.0183	CbGpPWpGaD
Paroxetine—CHRM4—Monoamine GPCRs—DRD4—conduct disorder	0.00134	0.0173	CbGpPWpGaD
Paroxetine—CHRM5—Monoamine GPCRs—DRD4—conduct disorder	0.00128	0.0166	CbGpPWpGaD
Paroxetine—SLC6A3—Monoamine Transport—SLC6A4—conduct disorder	0.00125	0.0162	CbGpPWpGaD
Paroxetine—CHRM4—Amine ligand-binding receptors—DRD4—conduct disorder	0.00113	0.0145	CbGpPWpGaD
Paroxetine—CHRM5—Amine ligand-binding receptors—DRD4—conduct disorder	0.00108	0.0139	CbGpPWpGaD
Paroxetine—TACR1—brain—conduct disorder	0.00103	0.0746	CbGeAlD
Paroxetine—CHRM4—brain—conduct disorder	0.000971	0.0702	CbGeAlD
Paroxetine—HTR2A—Monoamine GPCRs—DRD4—conduct disorder	0.000909	0.0117	CbGpPWpGaD
Paroxetine—CHRM1—Monoamine GPCRs—DRD4—conduct disorder	0.000905	0.0117	CbGpPWpGaD
Paroxetine—CHRM3—Monoamine GPCRs—DRD4—conduct disorder	0.000902	0.0116	CbGpPWpGaD
Paroxetine—TACR1—SIDS Susceptibility Pathways—SLC6A4—conduct disorder	0.000897	0.0116	CbGpPWpGaD
Paroxetine—CHRM2—Monoamine GPCRs—DRD4—conduct disorder	0.000893	0.0115	CbGpPWpGaD
Paroxetine—CHRM4—Monoamine GPCRs—HTR2A—conduct disorder	0.000875	0.0113	CbGpPWpGaD
Paroxetine—TACR1—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.000863	0.0111	CbGpPWpGaD
Paroxetine—CHRM5—Monoamine GPCRs—HTR2A—conduct disorder	0.000838	0.0108	CbGpPWpGaD
Paroxetine—HTR2A—Amine ligand-binding receptors—DRD4—conduct disorder	0.000765	0.00986	CbGpPWpGaD
Paroxetine—CHRM1—Amine ligand-binding receptors—DRD4—conduct disorder	0.00076	0.00981	CbGpPWpGaD
Paroxetine—CHRM5—brain—conduct disorder	0.000759	0.0549	CbGeAlD
Paroxetine—CHRM3—Amine ligand-binding receptors—DRD4—conduct disorder	0.000758	0.00978	CbGpPWpGaD
Paroxetine—CHRM2—Amine ligand-binding receptors—DRD4—conduct disorder	0.000751	0.00968	CbGpPWpGaD
Paroxetine—CHRM4—Amine ligand-binding receptors—HTR2A—conduct disorder	0.000736	0.00949	CbGpPWpGaD
Paroxetine—CHRM5—Amine ligand-binding receptors—HTR2A—conduct disorder	0.000705	0.00909	CbGpPWpGaD
Paroxetine—TACR1—SIDS Susceptibility Pathways—MAOA—conduct disorder	0.000675	0.0087	CbGpPWpGaD
Paroxetine—TACR1—GPCR ligand binding—CGA—conduct disorder	0.000657	0.00847	CbGpPWpGaD
Paroxetine—CHRM1—Monoamine GPCRs—HTR2A—conduct disorder	0.00059	0.00761	CbGpPWpGaD
Paroxetine—CHRM3—Monoamine GPCRs—HTR2A—conduct disorder	0.000588	0.00759	CbGpPWpGaD
Paroxetine—CHRM2—Monoamine GPCRs—HTR2A—conduct disorder	0.000583	0.00751	CbGpPWpGaD
Paroxetine—CHRM4—Regulation of Actin Cytoskeleton—WASF1—conduct disorder	0.000575	0.00741	CbGpPWpGaD
Paroxetine—CHRM5—Regulation of Actin Cytoskeleton—WASF1—conduct disorder	0.00055	0.0071	CbGpPWpGaD
Paroxetine—TACR1—SIDS Susceptibility Pathways—HTR2A—conduct disorder	0.00055	0.0071	CbGpPWpGaD
Paroxetine—CHRM2—brain—conduct disorder	0.000521	0.0377	CbGeAlD
Paroxetine—SLC6A3—brain—conduct disorder	0.000519	0.0375	CbGeAlD
Paroxetine—CHRM1—Amine ligand-binding receptors—HTR2A—conduct disorder	0.000496	0.0064	CbGpPWpGaD
Paroxetine—CHRM3—Amine ligand-binding receptors—HTR2A—conduct disorder	0.000495	0.00638	CbGpPWpGaD
Paroxetine—CHRM2—Amine ligand-binding receptors—HTR2A—conduct disorder	0.00049	0.00632	CbGpPWpGaD
Paroxetine—TACR1—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.000483	0.00623	CbGpPWpGaD
Paroxetine—CYP2D6—Melatonin metabolism and effects—MAOA—conduct disorder	0.000479	0.00617	CbGpPWpGaD
Paroxetine—TACR1—G alpha (q) signalling events—HTR2A—conduct disorder	0.000476	0.00614	CbGpPWpGaD
Paroxetine—SLC6A4—brain—conduct disorder	0.000476	0.0344	CbGeAlD
Paroxetine—CHRM1—brain—conduct disorder	0.000474	0.0343	CbGeAlD
Paroxetine—SLC6A3—Transmission across Chemical Synapses—GABRA2—conduct disorder	0.000456	0.00588	CbGpPWpGaD
Paroxetine—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.000426	0.00549	CbGpPWpGaD
Paroxetine—CHRM3—brain—conduct disorder	0.000424	0.0307	CbGeAlD
Paroxetine—SLC6A2—NRF2 pathway—SLC6A4—conduct disorder	0.000421	0.00542	CbGpPWpGaD
Paroxetine—SLC6A2—brain—conduct disorder	0.000419	0.0303	CbGeAlD
Paroxetine—HTR2A—GPCRs, Other—DRD4—conduct disorder	0.000404	0.00521	CbGpPWpGaD
Paroxetine—CHRM3—GPCRs, Other—DRD4—conduct disorder	0.000401	0.00517	CbGpPWpGaD
Paroxetine—CHRM2—GPCRs, Other—DRD4—conduct disorder	0.000397	0.00512	CbGpPWpGaD
Paroxetine—CHRM4—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.000396	0.00511	CbGpPWpGaD
Paroxetine—CHRM1—Regulation of Actin Cytoskeleton—WASF1—conduct disorder	0.000388	0.005	CbGpPWpGaD
Paroxetine—CHRM3—Regulation of Actin Cytoskeleton—WASF1—conduct disorder	0.000386	0.00498	CbGpPWpGaD
Paroxetine—CHRM2—Regulation of Actin Cytoskeleton—WASF1—conduct disorder	0.000383	0.00493	CbGpPWpGaD
Paroxetine—CHRM5—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.000379	0.00489	CbGpPWpGaD
Paroxetine—SLC6A3—NRF2 pathway—SLC6A4—conduct disorder	0.000373	0.0048	CbGpPWpGaD
Paroxetine—TACR1—GPCR downstream signaling—CGA—conduct disorder	0.000371	0.00479	CbGpPWpGaD
Paroxetine—TACR1—GPCR ligand binding—DRD4—conduct disorder	0.000368	0.00474	CbGpPWpGaD
Paroxetine—SLC6A4—Circadian rythm related genes—DRD4—conduct disorder	0.000356	0.00459	CbGpPWpGaD
Paroxetine—SLC6A3—Neuronal System—GABRA2—conduct disorder	0.000349	0.00451	CbGpPWpGaD
Paroxetine—SLC6A4—SIDS Susceptibility Pathways—MAOA—conduct disorder	0.000349	0.0045	CbGpPWpGaD
Paroxetine—CYP2C8—brain—conduct disorder	0.000344	0.0249	CbGeAlD
Paroxetine—TACR1—Signaling by GPCR—CGA—conduct disorder	0.000337	0.00435	CbGpPWpGaD
Paroxetine—TACR1—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000315	0.00406	CbGpPWpGaD
Paroxetine—CYP2B6—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.000312	0.00402	CbGpPWpGaD
Paroxetine—CYP2B6—brain—conduct disorder	0.000309	0.0223	CbGeAlD
Paroxetine—CHRM4—GPCR ligand binding—CGA—conduct disorder	0.000302	0.00389	CbGpPWpGaD
Paroxetine—TACR1—SIDS Susceptibility Pathways—EP300—conduct disorder	0.000291	0.00376	CbGpPWpGaD
Paroxetine—CHRM5—GPCR ligand binding—CGA—conduct disorder	0.000289	0.00373	CbGpPWpGaD
Paroxetine—SLC6A4—SIDS Susceptibility Pathways—HTR2A—conduct disorder	0.000285	0.00367	CbGpPWpGaD
Paroxetine—HTR2A—SIDS Susceptibility Pathways—SLC6A4—conduct disorder	0.000279	0.0036	CbGpPWpGaD
Paroxetine—CHRM4—G alpha (i) signalling events—DRD4—conduct disorder	0.000279	0.0036	CbGpPWpGaD
Paroxetine—CHRM2—SIDS Susceptibility Pathways—SLC6A4—conduct disorder	0.000274	0.00354	CbGpPWpGaD
Paroxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.000269	0.00346	CbGpPWpGaD
Paroxetine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.000267	0.00344	CbGpPWpGaD
Paroxetine—CHRM3—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.000266	0.00343	CbGpPWpGaD
Paroxetine—CYP2C8—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.000264	0.00341	CbGpPWpGaD
Paroxetine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.000264	0.0034	CbGpPWpGaD
Paroxetine—CHRM3—GPCRs, Other—HTR2A—conduct disorder	0.000261	0.00337	CbGpPWpGaD
Paroxetine—CHRM4—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.000259	0.00334	CbGpPWpGaD
Paroxetine—CHRM2—GPCRs, Other—HTR2A—conduct disorder	0.000259	0.00334	CbGpPWpGaD
Paroxetine—HTR2A—brain—conduct disorder	0.000252	0.0182	CbGeAlD
Paroxetine—CHRM5—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.000248	0.0032	CbGpPWpGaD
Paroxetine—TACR1—GPCR ligand binding—HTR2A—conduct disorder	0.00024	0.0031	CbGpPWpGaD
Paroxetine—CYP2D6—brain—conduct disorder	0.000229	0.0166	CbGeAlD
Paroxetine—CHRM1—Circadian rythm related genes—SLC6A4—conduct disorder	0.000227	0.00292	CbGpPWpGaD
Paroxetine—CHRM4—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.000222	0.00286	CbGpPWpGaD
Paroxetine—SLC6A3—Transmission across Chemical Synapses—COMT—conduct disorder	0.00022	0.00283	CbGpPWpGaD
Paroxetine—SLC6A3—Transmission across Chemical Synapses—MAOA—conduct disorder	0.000218	0.00281	CbGpPWpGaD
Paroxetine—CYP2D6—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.000217	0.0028	CbGpPWpGaD
Paroxetine—CYP2C9—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.000215	0.00277	CbGpPWpGaD
Paroxetine—CHRM1—Circadian rythm related genes—DRD4—conduct disorder	0.000213	0.00275	CbGpPWpGaD
Paroxetine—CHRM5—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.000212	0.00274	CbGpPWpGaD
Paroxetine—SLC6A2—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.000212	0.00274	CbGpPWpGaD
Paroxetine—HTR2A—SIDS Susceptibility Pathways—MAOA—conduct disorder	0.00021	0.00271	CbGpPWpGaD
Paroxetine—CHRM5—G alpha (q) signalling events—HTR2A—conduct disorder	0.000209	0.0027	CbGpPWpGaD
Paroxetine—TACR1—GPCR downstream signaling—DRD4—conduct disorder	0.000208	0.00268	CbGpPWpGaD
Paroxetine—CHRM2—SIDS Susceptibility Pathways—MAOA—conduct disorder	0.000206	0.00266	CbGpPWpGaD
Paroxetine—HTR2A—GPCR ligand binding—CGA—conduct disorder	0.000204	0.00264	CbGpPWpGaD
Paroxetine—CHRM1—GPCR ligand binding—CGA—conduct disorder	0.000203	0.00262	CbGpPWpGaD
Paroxetine—CHRM3—GPCR ligand binding—CGA—conduct disorder	0.000203	0.00261	CbGpPWpGaD
Paroxetine—CHRM2—GPCR ligand binding—CGA—conduct disorder	0.000201	0.00259	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—CGA—conduct disorder	0.000199	0.00257	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—DRD4—conduct disorder	0.000189	0.00243	CbGpPWpGaD
Paroxetine—SLC6A3—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.000188	0.00242	CbGpPWpGaD
Paroxetine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.000187	0.00241	CbGpPWpGaD
Paroxetine—CHRM2—G alpha (i) signalling events—DRD4—conduct disorder	0.000186	0.00239	CbGpPWpGaD
Paroxetine—HTR2A—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.000176	0.00226	CbGpPWpGaD
Paroxetine—CHRM1—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.000175	0.00225	CbGpPWpGaD
Paroxetine—CHRM3—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.000174	0.00224	CbGpPWpGaD
Paroxetine—CHRM2—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.000172	0.00222	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—CGA—conduct disorder	0.00017	0.0022	CbGpPWpGaD
Paroxetine—CHRM4—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000169	0.00218	CbGpPWpGaD
Paroxetine—CHRM4—GPCR ligand binding—DRD4—conduct disorder	0.000169	0.00218	CbGpPWpGaD
Paroxetine—SLC6A3—Neuronal System—COMT—conduct disorder	0.000168	0.00217	CbGpPWpGaD
Paroxetine—CHRM2—SIDS Susceptibility Pathways—HTR2A—conduct disorder	0.000168	0.00217	CbGpPWpGaD
Paroxetine—SLC6A3—Neuronal System—MAOA—conduct disorder	0.000167	0.00215	CbGpPWpGaD
Paroxetine—CYP2B6—Biological oxidations—COMT—conduct disorder	0.000167	0.00215	CbGpPWpGaD
Paroxetine—CYP2B6—Biological oxidations—MAOA—conduct disorder	0.000166	0.00214	CbGpPWpGaD
Paroxetine—ABCB1—brain—conduct disorder	0.000165	0.0119	CbGeAlD
Paroxetine—CYP2B6—Metapathway biotransformation—COMT—conduct disorder	0.000165	0.00212	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—CGA—conduct disorder	0.000163	0.00211	CbGpPWpGaD
Paroxetine—CHRM5—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000162	0.00209	CbGpPWpGaD
Paroxetine—CHRM5—GPCR ligand binding—DRD4—conduct disorder	0.000162	0.00209	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—WASF1—conduct disorder	0.00016	0.00206	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—CGA—conduct disorder	0.000155	0.002	CbGpPWpGaD
Paroxetine—SLC6A4—SIDS Susceptibility Pathways—EP300—conduct disorder	0.000151	0.00194	CbGpPWpGaD
Paroxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00015	0.00194	CbGpPWpGaD
Paroxetine—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00015	0.00193	CbGpPWpGaD
Paroxetine—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.000149	0.00192	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—CGA—conduct disorder	0.000148	0.00191	CbGpPWpGaD
Paroxetine—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.000148	0.0019	CbGpPWpGaD
Paroxetine—CHRM1—G alpha (q) signalling events—HTR2A—conduct disorder	0.000147	0.0019	CbGpPWpGaD
Paroxetine—CHRM3—G alpha (q) signalling events—HTR2A—conduct disorder	0.000147	0.00189	CbGpPWpGaD
Paroxetine—CHRM4—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000145	0.00187	CbGpPWpGaD
Paroxetine—CYP2C8—Biological oxidations—COMT—conduct disorder	0.000141	0.00182	CbGpPWpGaD
Paroxetine—CYP2C8—Biological oxidations—MAOA—conduct disorder	0.00014	0.00181	CbGpPWpGaD
Paroxetine—CYP2C8—Metapathway biotransformation—COMT—conduct disorder	0.000139	0.0018	CbGpPWpGaD
Paroxetine—CHRM5—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000139	0.00179	CbGpPWpGaD
Paroxetine—TACR1—GPCR downstream signaling—HTR2A—conduct disorder	0.000136	0.00175	CbGpPWpGaD
Paroxetine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.000132	0.0017	CbGpPWpGaD
Paroxetine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.000131	0.00169	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—HTR2A—conduct disorder	0.000123	0.00159	CbGpPWpGaD
Paroxetine—SLC6A4—Circadian rythm related genes—EP300—conduct disorder	0.000123	0.00159	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.00012	0.00155	CbGpPWpGaD
Paroxetine—CYP2D6—Biological oxidations—COMT—conduct disorder	0.000116	0.0015	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—CGA—conduct disorder	0.000116	0.00149	CbGpPWpGaD
Paroxetine—CYP2D6—Biological oxidations—MAOA—conduct disorder	0.000115	0.00149	CbGpPWpGaD
Paroxetine—CYP2C9—Biological oxidations—COMT—conduct disorder	0.000115	0.00148	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—CGA—conduct disorder	0.000115	0.00148	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—CGA—conduct disorder	0.000115	0.00148	CbGpPWpGaD
Paroxetine—HTR2A—GPCR ligand binding—DRD4—conduct disorder	0.000115	0.00148	CbGpPWpGaD
Paroxetine—CYP2D6—Metapathway biotransformation—COMT—conduct disorder	0.000114	0.00148	CbGpPWpGaD
Paroxetine—CYP2C9—Biological oxidations—MAOA—conduct disorder	0.000114	0.00147	CbGpPWpGaD
Paroxetine—CHRM1—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000114	0.00147	CbGpPWpGaD
Paroxetine—CHRM1—GPCR ligand binding—DRD4—conduct disorder	0.000114	0.00147	CbGpPWpGaD
Paroxetine—ABCB1—HIF-1-alpha transcription factor network—EP300—conduct disorder	0.000114	0.00146	CbGpPWpGaD
Paroxetine—CHRM3—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000114	0.00146	CbGpPWpGaD
Paroxetine—CHRM3—GPCR ligand binding—DRD4—conduct disorder	0.000114	0.00146	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—CGA—conduct disorder	0.000113	0.00146	CbGpPWpGaD
Paroxetine—CYP2C9—Metapathway biotransformation—COMT—conduct disorder	0.000113	0.00146	CbGpPWpGaD
Paroxetine—CHRM2—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000112	0.00145	CbGpPWpGaD
Paroxetine—CHRM2—GPCR ligand binding—DRD4—conduct disorder	0.000112	0.00145	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—DRD4—conduct disorder	0.000112	0.00144	CbGpPWpGaD
Paroxetine—CHRM4—GPCR ligand binding—HTR2A—conduct disorder	0.00011	0.00142	CbGpPWpGaD
Paroxetine—CHRM5—GPCR ligand binding—HTR2A—conduct disorder	0.000106	0.00136	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—CGA—conduct disorder	0.000105	0.00135	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—CGA—conduct disorder	0.000104	0.00135	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—CGA—conduct disorder	0.000104	0.00134	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—CGA—conduct disorder	0.000103	0.00133	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—CGA—conduct disorder	9.78e-05	0.00126	CbGpPWpGaD
Paroxetine—CHRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	9.76e-05	0.00126	CbGpPWpGaD
Paroxetine—CHRM3—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	9.73e-05	0.00125	CbGpPWpGaD
Paroxetine—CHRM2—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	9.63e-05	0.00124	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—DRD4—conduct disorder	9.55e-05	0.00123	CbGpPWpGaD
Paroxetine—ABCB1—Transmembrane transport of small molecules—GABRA2—conduct disorder	9.34e-05	0.0012	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CGA—conduct disorder	9.14e-05	0.00118	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—DRD4—conduct disorder	9.14e-05	0.00118	CbGpPWpGaD
Paroxetine—HTR2A—SIDS Susceptibility Pathways—EP300—conduct disorder	9.07e-05	0.00117	CbGpPWpGaD
Paroxetine—CHRM2—SIDS Susceptibility Pathways—EP300—conduct disorder	8.91e-05	0.00115	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CGA—conduct disorder	8.76e-05	0.00113	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—DRD4—conduct disorder	8.67e-05	0.00112	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—DRD4—conduct disorder	8.3e-05	0.00107	CbGpPWpGaD
Paroxetine—CHRM1—GPCR ligand binding—HTR2A—conduct disorder	7.43e-05	0.000958	CbGpPWpGaD
Paroxetine—CHRM3—GPCR ligand binding—HTR2A—conduct disorder	7.41e-05	0.000955	CbGpPWpGaD
Paroxetine—CHRM1—Circadian rythm related genes—EP300—conduct disorder	7.37e-05	0.00095	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—CGA—conduct disorder	7.35e-05	0.000948	CbGpPWpGaD
Paroxetine—CHRM2—GPCR ligand binding—HTR2A—conduct disorder	7.34e-05	0.000946	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—WASF1—conduct disorder	7.33e-05	0.000945	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—HTR2A—conduct disorder	7.28e-05	0.000938	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—WASF1—conduct disorder	7.02e-05	0.000905	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—DRD4—conduct disorder	6.47e-05	0.000835	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—DRD4—conduct disorder	6.44e-05	0.00083	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—DRD4—conduct disorder	6.42e-05	0.000827	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—DRD4—conduct disorder	6.35e-05	0.000819	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—CGA—conduct disorder	6.32e-05	0.000815	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—HTR2A—conduct disorder	6.23e-05	0.000803	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CGA—conduct disorder	6.2e-05	0.000799	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CGA—conduct disorder	6.17e-05	0.000795	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CGA—conduct disorder	6.15e-05	0.000793	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CGA—conduct disorder	6.09e-05	0.000785	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—HTR2A—conduct disorder	5.96e-05	0.000769	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—DRD4—conduct disorder	5.88e-05	0.000758	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—DRD4—conduct disorder	5.85e-05	0.000754	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—DRD4—conduct disorder	5.83e-05	0.000751	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—DRD4—conduct disorder	5.77e-05	0.000744	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—HTR2A—conduct disorder	5.66e-05	0.000729	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—HTR2A—conduct disorder	5.42e-05	0.000698	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—CGA—conduct disorder	5.35e-05	0.00069	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—DRD4—conduct disorder	5.12e-05	0.00066	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—WASF1—conduct disorder	4.97e-05	0.000641	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—WASF1—conduct disorder	4.94e-05	0.000637	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—WASF1—conduct disorder	4.93e-05	0.000635	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—DRD4—conduct disorder	4.9e-05	0.000632	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—WASF1—conduct disorder	4.88e-05	0.000629	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—conduct disorder	4.85e-05	0.000626	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CGA—conduct disorder	4.66e-05	0.000601	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CGA—conduct disorder	4.39e-05	0.000567	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CGA—conduct disorder	4.36e-05	0.000562	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—HTR2A—conduct disorder	4.2e-05	0.000542	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—HTR2A—conduct disorder	4.19e-05	0.00054	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—HTR2A—conduct disorder	4.15e-05	0.000535	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—EP300—conduct disorder	3.86e-05	0.000497	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—HTR2A—conduct disorder	3.81e-05	0.000492	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—HTR2A—conduct disorder	3.8e-05	0.00049	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—HTR2A—conduct disorder	3.76e-05	0.000485	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—DRD4—conduct disorder	3.47e-05	0.000448	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—DRD4—conduct disorder	3.45e-05	0.000445	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—DRD4—conduct disorder	3.44e-05	0.000444	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—DRD4—conduct disorder	3.41e-05	0.00044	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—HTR2A—conduct disorder	3.34e-05	0.000431	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—COMT—conduct disorder	3.32e-05	0.000428	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—MAOA—conduct disorder	3.29e-05	0.000425	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—HTR2A—conduct disorder	3.2e-05	0.000413	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—COMT—conduct disorder	2.85e-05	0.000368	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—MAOA—conduct disorder	2.83e-05	0.000366	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—COMT—conduct disorder	2.42e-05	0.000312	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—MAOA—conduct disorder	2.4e-05	0.000309	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—EP300—conduct disorder	2.33e-05	0.0003	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—HTR2A—conduct disorder	2.25e-05	0.000291	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—HTR2A—conduct disorder	2.25e-05	0.00029	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—HTR2A—conduct disorder	2.22e-05	0.000287	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—COMT—conduct disorder	2.11e-05	0.000272	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—MAOA—conduct disorder	2.09e-05	0.00027	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—COMT—conduct disorder	1.98e-05	0.000256	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—MAOA—conduct disorder	1.97e-05	0.000254	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—COMT—conduct disorder	1.97e-05	0.000254	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—MAOA—conduct disorder	1.95e-05	0.000252	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—conduct disorder	1.89e-05	0.000244	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—EP300—conduct disorder	1.77e-05	0.000228	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—EP300—conduct disorder	1.7e-05	0.000219	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—EP300—conduct disorder	1.42e-05	0.000183	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—EP300—conduct disorder	1.22e-05	0.000158	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—EP300—conduct disorder	1.2e-05	0.000155	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—EP300—conduct disorder	1.19e-05	0.000154	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—EP300—conduct disorder	1.19e-05	0.000153	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—EP300—conduct disorder	1.18e-05	0.000152	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—EP300—conduct disorder	1.04e-05	0.000134	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—EP300—conduct disorder	9.03e-06	0.000116	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—EP300—conduct disorder	8.51e-06	0.00011	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—EP300—conduct disorder	8.43e-06	0.000109	CbGpPWpGaD
